Empiri provides empirical drug sensitivity data through E-slice analysis and single-cell RNA sequencing to assess individual tumor responses to cancer therapies. This approach enhances treatment effectiveness and minimizes adverse side effects by delivering personalized drug response information prior to treatment decisions.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for determining drug sensitivity in cancer treatment rely heavily on genomic or histologic diagnoses, which may not accurately predict individual tumor responses to specific therapies. This can lead to ineffective treatments, increased side effects, and higher healthcare costs.
Solution
Empiri offers empirical drug sensitivity data through E-slice analysis and single-cell RNA sequencing to provide personalized insights into how individual tumors respond to cancer therapies. By directly assessing the tumor tissue's response to specific drugs, Empiri's approach aims to bridge the gap between clinical research and patient care, optimizing treatment decisions. Their clinically validated method is cancer-agnostic and independent of genomic or histologic diagnosis, offering a pragmatic approach to personalized cancer treatment. Empiri's services provide early response data, enabling agile decisions on clinical trial design and enrollment.
Target Audience
Empiri's primary customers are pharmaceutical companies conducting clinical trials and researchers in the Texas Medical Center (TMC) area seeking to improve cancer treatment outcomes.
Features
- E-slice analysis using biopsy cores or surgical material to assess drug sensitivity.
- End-to-end single-cell RNA sequencing service, from tissue dissociation to bioinformatics analysis.
- Immune profiling to decipher the complexity of each cancer ecosystem.
- Cutting-edge correlative study services for pharmaceutical research and clinical trials.
- Early response data to enable agile decisions on clinical trial design and enrollment.